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Objective: Endovascular aneurysm repair (EVAR) became an increasingly preferred modality for abdominal aortic
aneurysm (AAA) repair both in elective AAA repair (el-EVAR) and EVAR of a ruptured AAA (r-EVAR) setting. Ruptured
AAAs usually have more hostile anatomies and less time for planning. Consequently, more complications may arise after
r-EVAR. The purpose of this study was to compare mi-term outcomes between r-EVAR and el-EVAR.
Methods: A retrospective cohort analysis of patients undergoing EVAR from 2000 to 2015 at a tertiary institution was
performed. Patients with previous aortic surgery, nonatherosclerotic AAA and isolated iliac aneurysms were excluded.
In-hospital casualties or patients who were intraoperatively converted to open repair were also excluded. For the
midterm outcome analysis, only patients with at least two postoperative examinations (a 30-day computed
tomography scan and a second postoperative examination performed 6 months or later) were considered. The pri-
mary end point was freedom from aneurysm-related complications (a composite of type I or III endoleak, aneurysm
sac growth, migration of more than 5 mm, device integrity failure, AAA-related death, late postimplant rupture, or
AAA-related secondary intervention). Freedom from secondary interventions, neck-related events (defined as a
composite of type IA endoleak, migration of more than 5 mm, or preemptive neck-related secondary intervention)
and late survival were secondary end points. The impact of device instructions for use (IFU) compliance on neck
events was also assessed.
Results: The study included 565 patients (65 r-EVAR and 500 el-EVAR). Eighty-two patients were treated outside prox-
imal neck IFU, 13 in the r-EVAR group (21.3%) and 69 (14.5%) in the el-EVAR (P ¼ .16). During the index hospitalization, there
were more complications (12.3% vs 3.2%; P ¼ .001) and reinterventions (12.3% vs 2.8%; P < .001) in the r-EVAR group. After
discharge, median clinical follow-up time was 4.3 years (interquartile range, 2.1-7.0 years) without differences between
both groups. Five-year freedom from AAA-related complications was 53.9% in the r-EVAR group and 65.4% in the
el-EVAR (P ¼ .21). In multivariable analysis the r-EVAR group was not at increased risk for late complications (hazard ratio
[HR], 0.94; 95% confidence interval [CI], 0.54-1.61; P ¼ .81). Five-year freedom from neck-related events was 74% in r-EVAR
and 82% in the el-EVAR group (P ¼ .345). Patients treated outside neck IFU were at greater risk for neck-related events
both in r-EVAR (HR, 6.5; 95% CI, 1.8-22.9; P ¼ .004) and el-EVAR group (HR, 2.6; 95% CI, 1.5-4.5; P < .001). Freedom from
secondary interventions at 5 years was 63.0% for r-EVAR and 76.9% for el-EVAR (P ¼ .16). Survival at 5 years was 68.8% in
the r-EVAR group and 73.3% in the el-EVAR group (P ¼ .30).
Conclusions: Durable and sustainable midterm outcomes were found for both r-EVAR and el-EVAR patients who sur-
vived the postoperative period. Patients treated outside the IFU are at greater risk for late complications. Surveillance
protocols may be tailored according to individual anatomy and IFU compliance rather than timing of repair. (J Vasc Surg
2019;-:1-10.)
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d Type of Research: Retrospective analysis of a pro-
spectively collected single-center database
d Key Findings: Comparison of outcome of 565 early
survivors of endovascular aneurysm repair (EVAR)
for ruptured (n ¼ 65) and elective (n ¼ 500) abdom-
inal aortic aneurysms who had at least two postoper-
ative imaging examinations revealed durable results
in both groups, despite more hostile anatomy and
less time for planning after ruptured EVAR. No differ-
ences at baseline were found regarding sealing
length and instructions for use adherence.
d Take Home Message: This study suggests that dura-
ble results can be reached in early survivors after
both ruptured and elective EVAR as long as instruc-
tions for use are respected and proper sealing is
obtained.
2 Oliveira-Pinto et al Journal of Vascular Surgery
--- 2019Endovascular aneurysm repair for ruptured aortic
abdominal aneurysms (r-EVAR) has been increasingly
used owing to its potential short-term benefits on survival
and morbidity.1,2 However, the possibility of developing
aneurysm-related complications remains the main
drawback and lifelong surveillance is thereforewarranted.3
Previousdata suggest thatpatientswho survive theperiop-
erativeperiod followingr-EVARmayhavesimilar long-term
survival rates when compared with patients undergoing
elective EVAR (el-EVAR).4 However, r-EVAR is frequently
performed in more hostile anatomy, with less time to
plan and endograft selection is limited by the available
stock.5 Consequently, these patients may be at greater
risk of developing complications than those treated elec-
tively. Although there are some reports comparing out-
comes following r-EVAR and el-EVAR, data regarding
longer term follow-up remains scarce.6,7 The purpose of
this study was to compare midterm outcomes between
r-EVAR and el-EVAR in patients surviving in-hospital stay.
METHODS
Design and population. A retrospective cohort study
was designed based on a prospectively maintained data-
base, including all patients undergoing standard EVAR in
a single tertiary referral center in The Netherlands.
Informed consent was not required according to institu-
tional policy on retrospective research. All consecutive
patients undergoing EVAR between January 2000 and
December 2015 for infrarenal AAA were included. Pa-
tients with previous aortic surgery or with a diagnosis
other than degenerative AAA (ie, anastomotic, infectious,
or isolated iliac aneurysms) were excluded. Additionally,
patients who died in the perioperative period (defined
as death during the index admission) or who were intra-
operatively converted to open repair were excluded from
the analysis. Because our population usually performs
first postoperative computed tomography angiography
(CTA) during admission, only patients with at least two
postoperative imaging examinations (a first 30-day
contrast-enhanced CTA and a second examination,
performed more than 6 months after EVAR), were
considered for this midterm follow-up analysis.
Postoperative surveillance. At the beginning of the
study period, CTA was performed at 1, 6, and 12 months,
and yearly thereafter. However, the 6-month CTA has
been progressively reserved for selected patients with or
at an increased risk of developing aneurysm-related
complications. Alternatively, if patients were considered
by the treating physician to be at low risk of complica-
tions or had renal function impairment, color duplex
ultrasound examination or a noncontrast CT scan was
preferred during follow-up. Upon the detection of an
adverse event on these imaging modalities, such as
enlargement of more than 5 mm or an endoleak other
than a type II endoleak, the patient would undergo CTA.Data management. Baseline demographics and
anatomic measurement were collected at the time of
the intervention. All subsequent follow-up data were
prospectively obtained upon outpatient visits and/or
patient record consult at regular, predefined intervals.
Date of death was retrieved from hospital records and
from the Dutch Center Bureau of Statistics.
Image analysis and measurements. All measurements
(diameters, lengths, angles, and volumes) were obtained
on CT imaging using semiautomatically generated cen-
ter lumen line reconstructions performed on dedicated
reconstruction software (3mensio Vascular 4.2; Medical
Imaging B.V., Bilthoven, The Netherlands). All imaging
data were acquired by three observers with experience
in image analysis (J.O.P., N.O., F.B.G.).
Proximal and distal sealing lengths were measured on
the first postoperative CTA (30-day CTA). The sealing
length was considered to be the distance where the
entire circumference of the aortic and iliac vessel walls
and the endograft are completely adjacent. The method
of sealing length measurement has been described
elsewhere.8 Sufficient postoperative seal was considered
if a minimum seal length of 10 mm was measured prox-
imally and distally according to previous reports.8,9
In a previous report, our group has demonstrated high
rates of interobserver agreement regarding aneurysm
diameter, neck diameter, neck length, and proximal
seal length measurements with this method.8,10 Aneu-
rysm volume and neck angulation were also measured
according to previously validated method.11,12
Aneurysm neck length was defined as the distance
from the lowermost renal artery to the level where the
aortic diameter increases by more than 10%. Aneurysm
neck thrombus and calcification were categorized
according to infrarenal aortic neck circumferential
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ing to published methodology.13
After scrutiny of the preoperative CT scan, compliance
with the device manufacturers’ instructions for use (IFU)
for the specific device implanted was assessed.
Definitions. Patient comorbidities and aneurysm-
related outcomes were reported according to the
recommendations from the Society for Vascular Surgery/
American Association of Vascular Surgery ad hoc
Committee for Standardized Reporting Practices in
Vascular Surgery.14 An AAA was considered ruptured
when evidence of retroperitoneal bleeding was present
on the preoperative CTA. Intraoperative complications
were considered to have occurred if the device was not
deployed at the intended position, if type I or III endoleak
or graft obstruction was present, or if unplanned endo-
vascular or surgical procedures were necessary. Compli-
cations during the index hospitalization (or <30 days)
were defined as type I or III endoleak, graft obstruction/
limb ischemia, or if unplanned endovascular or surgical
procedures were necessary within this timeframe.
AAA-related complications were defined as a compos-
ite of the following: direct (type I or III) endoleak, aneu-
rysm sac expansion or more than 5% in volume or
5 mm in diameter, migration of more than 5 mm,
graft infection or thrombosis, device integrity failure,
AAA-related death, late postimplant rupture, or any
AAA-related secondary intervention. Secondary interven-
tions were considered to be AAA related if performed to
resolve or prevent a possible complication associated
with the initial treatment of the AAA and included
proximal cuff and stent implant, distal extension,
catheter-based thrombolysis, iliac angioplasty, coil or
glue embolization of aortic branch vessels, balloon
thrombectomy, femoral-femoral crossover, conversion
to open repair, and open or laparoscopic ligation of
collaterals.
Sac growth was defined as a more than 5% increase in
aneurysm sac volume or as a more than 5 mm increase
in sac diameter. A neck-related event was defined as a
composite of type IA endoleak, neck-related secondary
intervention, or migration of more than 5 mm.
End points. The primary end point was freedom from
AAA-related complications. Individual components of
the composite outcome were used as secondary end
points: freedom from secondary intervention, sac growth,
types I and III endoleak, device migration of more than
5 mm, conversion to open repair, and AAA-related death
or AAA rupture. Additionally, neck-related events and
overall mortality were also assessed. Impact on neck IFU
compliance on neck event was also analyzed.
Statistical analysis. Categorical variables are presented
as count and percentage, and compared using the Pear-
son’s c2 test. Continuous variables are presented as meanand standard deviation or as median and interquartile
range (IQR). Differences between groups were analyzed
using the Mann-Whitney U test for independent sam-
ples with non-normal distributions or with the Student’s
t-test and significance with the independent samples
test for nonrelated variables with normal distributions.
Survival curves for freedom from aneurysm-related
adverse events were estimated by Kaplan-Meier
methods, and equality was evaluated with the Mantel-
Cox log-rank test. Aneurysm-related outcome variables
were assessed by Cox hazards regression models. Age
and gender were included a priori in the Cox model.
Multivariate regression was performed adjusting for
baseline clinical and morphologic features differently
distributed among groups at a P value of less than .1 level.
Confidence intervals (CIs) of 95% were used and statisti-
cal significance was considered if the P was less than
.05. All statistical analysis was performed using SPSS
24.0 (IBM, Armonk, NY).
RESULTS
From January 2000 to December 2015, 660 patients
underwent standard EVAR. Sixty-four patients were
considered not eligible for this study, including 33 anas-
tomotic or other pseudoaneurysms, 21 isolated iliac an-
eurysms, 9 infectious aneurysms, and 1 traumatic rupture.
Among the remaining study population of 596 patients
(89 r-EVAR and 507 el-EVAR), 26 patients died during the
index hospitalization (22 r-EVAR and 4 el-EVAR) and 5
patients were intraoperatively converted to open repair
(4 r-EVAR and 1 el-EVAR), leaving a final study population
of 565 patients, 65 r-EVAR (11.5%) and 500 el-EVAR
(88.5%) patients. Mean age was 73.2 6 7.6 years and
89.9% were male. Baseline demographics are presented
in Table I.
Baseline anatomic features were distinct among
groups. In the r-EVAR group, the aneurysms were larger
(median diameter, 76 mm [IQR, 62-89 mm], vs 60 mm
[IQR, 54-68 mm]; P < .001), the proximal necks were
shorter (neck <15 mm: 21.3% vs 8.6%; P ¼ .002) and
more angulated (a angle >45: 21.3% vs 10.3%; P ¼ .011;
b-angle >60: 31.1% vs 17.4%; P ¼ .010). Among the
r-EVAR group, a higher proportion of patients were
treated using aortouni-iliac devices (33.3% vs 3.2%;
P < .001; Table I).
A preoperative CT scan of adequate quality was missing
in 27 patients (4 in r-EVAR and 23 in el-EVAR). Eighty-two
patients were treated outside proximal neck IFU, 13
(21.3%) in the r-EVAR group and 69 (14.5%) in the
el-EVAR (P ¼ .16). Among patients outside neck IFU, in
16 (20%) IFU violation was owing to neck length
(2 r-EVAR and 14 el-EVAR) and 66 (80%) patients owing
to neck angulation (11 r-EVAR and 55 el-EVAR).
Proximal and distal sealing of 10 mm or greater at the
30-day CT imaging was found in 44 r-EVAR patients
(74.6%) and in 360 el-EVAR patients (77.8%) (P ¼ .84).
Table I. Baseline demographic and morphological characteristics
Variable r-EVAR (n ¼ 65) el-EVAR (n ¼ 500) P value
Male sex 60 (92.3) 448 (89.6) .50
Age, years 71.53 6 8.56 72.41 6 7.49 .38
SVS/AAVS cardiac status $2b,c 7 (15.2) 89 (18.3) .60
Hypertensionb 38 (74.5) 352 (70.8) .58
Smokingb 33 (71.7) 370 (74.4) .69
Diabetesb 9 (18.8) 81 (16.3) .67
PADb 10 (21.3) 76 (15.3) .29
eGFR <60 mL/min/1.73 m2 a 22 (38.2) 127 (26.5) .06
AAA Øa 76 [62-89] 60 [54-68] <.001
AAA volume 339 [202-490] 180 [135-248] <.001
Reverse tapper configurationb 20 (32.8) 102 (21.4) .046
Proximal neck Øb 25 [23-28] 25 [23-27] .14
Proximal Neck Ø > 28 mm 11 (18.0) 72 (15.1) .55
Proximal neck length, mmb 20 [15-30.3] 28 [20-39] <.001
Proximal neck length <15 mm 13 (21.3) 41 (8.6) .002
Neck thrombus >25%b 21 (34.4) 154 (32.3) .74
Neck calcification >25%b 10 (16.4) 103 (21.6) .35
a Angleb 22.5 [15.3-44] 21 [11-33] .041
a Angle >45 b 13 (21.3) 49 (10.3) .011
b Angleb 44.7 [25.3-63.1] 36 [24-52] 0.14
b Angle >60 b 20 (19.4) 83 (17.4) .004
Proximal sealing length, mm 17.5 [13.3-22.7] 20 [13-26] .046
PSL >10 mm 50 (83.3) 394 (84.9) .75
Right iliac sealing length, mm 29 [20-44] 29 [20-40] .81
Left iliac sealing length, mm 26 [17-35] 29 [20-39] .12
Proper sealing proximal and distal 44 (74.6) 360 (77.8) .84
AUI device 20 (33.3) 16 (3.2) <.001
Endograft
Endurant 44 (67.7) 258 (51.6)
Excluder 19 (29.3) 191 (38.8)
Talent 2 (3.0) 12 (2.4)
Other e 39 (7.8)
Outside neck IFUb 13 (21.3) 69 (14.5) .16
AAA, Abdominal aortic aneurysm; AAVS, American Association for Vascular Surgery; AUI, aortouni-iliac; Ø, Diameter; eGFR, estimated glomerular
filtration rate; el-EVAR, elective endovascular aneurysm repair; IFU, instructions for use; PAD, peripheral arterial disease; PSL, proximal sealing length;
r-EVAR, endovascular repair of a ruptured abdominal aortic aneurysm; SVS, Society for Vascular Surgery.
Continuous data are presented as median [interquartile range] and categorical data as count (percentage). Other data are mean 6 standard
deviation.
aMissing 1%-3% of baseline data.
bMissing 3%-6% of baseline data.
cAccording to the SVS/AAVS medical comorbidity grading system.
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there was no difference among groups regarding intrao-
perative complications (13.8% r-EVAR vs 10.6% el-EVAR;
P ¼ .43). There were three intraoperative type IA endo-
leaks in the r-EVAR group, all of them solved with prox-
imal cuff placement. Twenty-six intraoperative type IA
endoleak were observed in the el-EVAR group: 16 of
them needed a proximal extension, 7 patients solved
with ballooning only, and in 3 patients a small type IA
persisted and were kept under surveillance.During the index hospitalization, more complications
(12.3% vs 3.2%; P ¼ .001) and secondary interventions
(12.3% vs 2.8%; P ¼ .001) were observed in the r-EVAR
group. Three r-EVAR patients needed decompressive lap-
arotomies owing to abdominal compartment syndrome.
Two r-EVAR patients and three el-EVAR had a type
IA endoleak detected in the postoperative CT scan
and both underwent proximal cuff extension. One
88-year-old el-EVAR patient had a small type IA endo-
leak detected but was kept under strict surveillance.
Table II. Intraoperative and in-hospital outcomes
r-EVAR (n ¼ 65) el-EVAR (n ¼ 500) P value
Intraoperative complication 9 (13.8) 53 (10.6) .43
Type IA endoleak 3 (4.6) 26 (5.2) .84
Type IB endoleak 2 (3.1) 6 (1.2) .23
Type III endoleak 0 (0) 1 (.2) .72
Other 2 (3.1) 18 (3.6) .83
Intraoperative unexpected interventions 8 (12.3) 38 (7.6) . 19
Proximal cuff 3 (4.4) 22 (4.6) .94
Distal extension 4 (6.2) 6 (1.2) .004
Conversion to AUI 1 (1.5) 2 (0.4) .24
Renal stent 0 (0) 4 (.8) .47
Iliac PTA 1 (1.5) 6 (1.2) .039
Complications at 30 days 8 (12.3) 16 (3.2) .001
Type Ia 2 (3.1) 4 (.8) .09
Limb ischemia 1 (1.5) 8 (1.4) .97
Other 4 (6.2) 1 (1.2) <.001
Reinterventions at 30 days, patients 8 (12.3) 14 (2.8) <.001
Proximal cuff 1 (1.5) 4 (.6) .39
Distal extension 1 (1.5) 0 (0) .006
Thrombectomy/PTA 1 (1.5) 8 (1.6) .97
Other 5 (7.4) 4 (.8) <.001
AUI, Aortouni-iliac; el-EVAR, elective endovascular aneurysm repair; r-EVAR, endovascular repair of a ruptured abdominal aortic aneurysm; PTA,
percutaneous transluminal angioplasty.
Dichotomous data are presented as count (%).
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had an asymptomatic limb occlusion, which was visual-
ized in the postoperative CTA; both underwent throm-
bolysis and subsequent distal extension. In the el-EVAR
group, partial overstenting of the renal artery was noted
and the patient underwent renal stenting to avoid a sub-
sequent occlusion. Finally, limb compression at the aortic
bifurcation level was identified in one patient and
subsequent percutaneous transluminal angioplasty was
performed. Detailed data of intraoperative and perioper-
ative outcomes are presented in Table II.
Aneurysm-related complications. Two postoperative
imaging examinations were available in 527 patients
(60 r-EVAR and 467 el-EVAR) and these patients were
accountable for midterm analysis. Thirty-eight patients
did not have two postoperative examinations: 12 patients
were followed elsewhere after EVAR, 22 patients died
before performing second postoperative examination (4
r-EVAR [6.2%] and 18 el-EVAR [3.6%] patients) and 4
patients choose not to have further follow-up.
The median clinical follow-up was 4.3 years (IQR, 2.1-
7.0 years) and was similar between groups (r-EVAR,
4.0 years [IQR, 2.0-5.6 years] and el-EVAR, 4.2 years [IQR,
2.1-7.0 years]; P ¼ .29) (Table III).
After discharge, 21 r-EVAR patients (35%) had
aneurysm-related complications and these occurred in146 patients (31.3%) in the el-EVAR group (Table III). The
3-year and 5-year freedom from AAA-related complica-
tions were 73.1% (n ¼ 24; standard error [SE], 0.066) and
53.9% (n ¼ 13; SE, 0.083) in the r-EVAR group and
80.6% (n ¼ 233; SE, 0.020) and 65.4% (n ¼ 151; SE, 0.027)
in the el-EVAR, respectively (P ¼ .21) (Fig 1). Individual
components of the latter outcome are reported in
Table III. In an adjusted Cox proportional hazards model,
the r-EVAR group was not at an increased risk for late
complications (HR, 0.94; 95% CI, 0.54-1.61; P ¼ .81)
(Table IV).
Aneurysm sac growth occurred similarly between
groups (11 r-EVAR [18.3%] and 86 el-EVAR [18.4%]; P ¼
.98). Postimplant ruptures occurred in eight patients,
three r-EVAR patients (5.0%) and five among el-EVAR
(1.1%; P ¼ .052), resulting in death in four patients, two
(3.3%) r-EVAR and two el-EVAR (0.4%; P ¼ .015).
Eighty-five patients had neck-related events: 11 r-EVAR
(18.3%) and 74 el-EVAR (15.8%) patients. The 3- and
5-year freedom from neck-related events was 87%
(n ¼ 30; SE, 0.051) and 74% (n ¼ ; SE, 0.075) in r-EVAR
and 90% (n ¼ 272; SE, 0.015) and 83% (n ¼ 174; SE,
0.022) in the el-EVAR group (P ¼ .35) (Fig 2). There were
no differences between r-EVAR and el-EVAR regarding
type IA endoleak occurrence (3 [5.0%] vs 32 [6.9%];
P ¼ .59), or migration (8 [13.8%] vs 38 [8.3%]; P ¼ .17).
Patients treated outside neck IFU were at greater risk
Table III. Aneurysm-related complications after discharge
Outcome measure r-EVAR (n ¼ 60) el-EVAR (n ¼ 467) P value
Follow-up, years 4.0 [2.0-5.6] 4.2 [2.1-7.0] .29
Overall mortality 25 (41.7) 182 (39.0) .30a
Aneurysm-related complications, patients 21 (35.0) 146 (31.3) .21a
Postimplant rupture 3 (5.0) 5 (1.1) .052
Secondary endoleaks, patients 13 (21.7) 123 (26.3) .436
Type IA 3 (5.0) 32 (6.9) .59
Type IB 2 (3.3) 22 (4.7) .63
Type II 11 (18.3) 87 (18.6) .96
Type III 1 (1.7) 4 (0.9) .54
Sac growth 11 (18.3) 86 (18.4) .98
Migration >5 mm 8 (13.8) 38 (8.3) .17
Limb thrombosis 4 (6.7) 14 (3.0) .14
Endograft infection 0 (0) 5 (1.1) .42
Secondary interventions, patients 16 (26.7) 101 (21.6) 0.16a
Proximal cuff/Palmaz stent 4 (6.7) 30 (6.4) .94
Conversion AUI 0 (0) 3 (0.6) .53
Iliac PTA 0 (0) 4 (0.9) .47
Distal extension 10 (16.7) 36 (7.7) .02
Thrombolysis þ PTA 1 (1.7) 6 (1.3) .80
Thrombectomy þ limb extension/PTA 1 (1.7) 7 (1.5) .92
Renal stenting 0 (0) 1 (0.2) .72
Open/laparoscopic ligation of collaterals 0 (0) 9 (1.9) .28
Percutaneous embolization of IMA/lumbars 0 (0) 11 (2.4) .23
Relining 1 (3.3) 8 (1.7) .39
Open conversion 5 (8.3) 18 (3.9) .11
AUI, Aortouni-iliac; el-EVAR, elective endovascular aneurysm repair; IMA, internal mammary artery; r-EVAR, endovascular repair of a ruptured
abdominal aortic aneurysm; PTA, percutaneous transluminal angioplasty.
Dichotomous data are presented as count (%). Continuous data presented as median [interquartile range].
aP values obtained from log-rank test.
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95% CI, 1.8-22.9; P ¼ .004] and in the el-EVAR group (HR,
2.6; 95% CI, 1.5-4.5 P < .001).
Secondary interventions. After the index hospitaliza-
tion for EVAR, 155 secondary interventions were per-
formed in 117 patients (16 r-EVAR [26.7%] vs 101 el-EVAR
[21.6%]). Freedom from secondary interventions at 3 and
5 years were 83.0% (n ¼ 27; SE, 0.054) and 63.0% (n ¼ 18;
SE, 0.081) for r-EVAR and 87.0% (n ¼ 263; SE, 0.017) and
76.9% (n ¼ 16; SE, 0.025) for el-EVAR (P ¼ .16) (Fig 3).
Detailed data regarding secondary interventions are
presented in Table III.
In multivariable regression analysis, the risk of second-
ary intervention was not higher among r-EVAR patients
(HR 0.97; 95% CI, 0.50-1.86; P ¼ .93; Table IV). In the
r-EVAR group, three patients were electively converted
to open repair owing to type IA endoleak (one of them
had a proximal cuff placed but type IA endoleak reoc-
curred). In the el-EVAR, group 26 patients were inter-
vened owing to type IA endoleaks (16 proximal cuffs, 9
conversions to open repair, and 1 patient underwentrelining with gaining of proximal seal). In six patients pre-
senting with type IA endoleak, no procedure was carried
out: one patient owing to spontaneous sealing, three
patients owing to refusal for further intervention, and
two patients owing to unsuitable anatomy for endovas-
cular repair and unacceptable risk for open repair.
All-cause mortality and AAA-related mortality. During
the study period, death beyond index hospitalization
occurred in 207 (39.3%) patients: 25 in the r-EVAR group
(41.7%) and 182 in el-EVAR group (39.0%). Survival at 3
and 5 years was 76.6% (n ¼ 41; SE, 0.057) and 68.8%
(n ¼ 33; SE, 0.063) in the r-EVAR group and 84.4% (n ¼ 331;
SE, 0.018) and 73.3% (n ¼ 190; SE, 0.025), respectively, in
the el-EVAR group, (P ¼ .30) (Fig 4). Overall survival
including patients previously excluded owing to lack of
two postoperative imaging examinations is shown in the
Supplementary Fig (online only). Of these, nine deaths
were AAA related, two in the r-EVAR group and seven in
the el-EVAR group. In these patients, postimplant
rupture was the cause in four patients (time frame of
death: 1.9, 3.0, 3.3, and 8.0 years after EVAR), endograft
Fig 1. Kaplan-Meier curve for freedom from aneurysm-
related complications after endovascular repair of a
ruptured abdominal aortic aneurysm (r-EVAR) and elec-
tive endovascular aneurysm repair (el-EVAR). Kaplan-
Meier curves only include data from patients with two
postoperative examinations. SE, Standard error.
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EVAR), and owing to postoperative complications after a
secondary intervention in three patients (at 3, 10, and
15 years after EVAR). In multivariable analysis correcting
for baseline differences, r-EVAR was not an independent
predictor for late overall mortality (HR, 0.62; 95% CI, 0.35-
1.11; P ¼ .11) (Table IV).
DISCUSSION
Patients with patients with a ruptured AAA have more
complex anatomies and require an expeditious preoper-
ative planning. Therefore, a theoretical greater risk of
complications might be anticipated after r-EVAR after
the initial hospitalization period. Our results suggest
that, excluding the early perioperative period, sustain-
able midterm outcomes can be achieved in both
ruptured and elective settings.
Comparative data on late outcomes following r-EVAR
and el-EVAR is scarce. Bastos Gonçalves et al15 had previ-
ously reported that r-EVAR was not a significant risk fac-
tor for late complications when compared with el-EVAR
(HR, 0.87; 95% CI, 0.43-1.79; P ¼ .71).15 Although some
patients figuring in this multicentric report are also
included in our current study, other patients treated at
our center were added as well as follow-up was
extended. Furthermore, our r-EVAR group was
compared with an el-EVAR group obtained from the
same population treated by the same surgical team dur-
ing the same study period. However, this factor may limit
the generalizability of the presented results to other cen-
ters, the risk of bias inherent to the repair itself as well as
differences in the study population’s genetic background
is thus reduced in our analyses. Also Broos et al6 found no
differences regarding secondary interventions among
r-EVAR and el-EVAR patients in a single-center report
including 863 patients (90 r-EVAR with a medianfollow-up of 21 months and 773 el-EVAR patients with a
median follow-up of 38 months). At first glance, our
results are in agreement with these authors. Still, in this
study a there was a tendency toward higher reinterven-
tion rates was observed in r-EVAR group (21.8% vs 15.8%
at 5 years; P ¼ .064). However, an adjusted analysis is
not provided, which may limit conclusions regarding
timing of repair and incidence of secondary interven-
tions. Even though baseline anatomy was significantly
more hostile among r-EVAR patients in our cohort, no
difference was found regarding neck IFU compliance
between groups. Additionally, in our cohort, the number
of patients with more than 10 mm of proximal and distal
seal on the initial postoperative seal was also similar
between groups. Previous reports have demonstrated
that absence of endoleak at 30 days in conjunction
with adequate proximal and distal seal represent a reli-
able proxy of a low risk of complications, at least up to
5 years after the intervention,8,9 and that it may be safe
to have a less stringent surveillance program for this
patient group. Consequently, we hypothesized that if
those two conditions are respected, r-EVAR patients
may follow the same less stringent surveillance. However,
it is important to note that both freedom from AAA-
related complications and freedom from secondary in-
terventions seem to have decreased more abruptly
among the r-EVAR cohort from 3 years onward, although
these differences were not statistically significant; howev-
er, they are potentially clinically relevant.
We consider that our study’s sample size and the avail-
able follow-up may have limited the power to detect a
statistical difference and thus advise caution when inter-
preting our results. A prospective study, designed as a
noninferiority study and with adequate power calcula-
tion, would add strength to the conclusion. More studies
with longer term follow-up are needed to safely advice
on the possibilities of changing the intensity of surveil-
lance programs after r-EVAR. Still, after multivariable
analysis, correcting for baseline differences among
groups, in an attempt to isolate the effect of timing of
repair no greater risk was found for r-EVAR patients
(HR, 0.94; 95% CI, 0.54-1.61; P ¼ .81). Our study is in line
with the 3-year results of the IMPROVE Trial reporting
21% of patients (26/125, per protocol analysis) undergoing
reintervention between 90 days and 3 years after EVAR.
Secondary intervention rates we report here may seem
slightly higher to the IMPROVE trial, but our cohort was
followed for a longer period of time. Additionally, in our
study only AAA-related reinterventions are reported, as
defined by Society for Vascular Surgery reporting stan-
dards, in the IMPROVE trial also reinterventions not
graft-related were considered.14,16,17
However, using the same 3-year cutoff in our
study, freedom from secondary interventions was
83% (n ¼ 27) which is similar to described the IMPROVE
trial: 38 reinterventions in 26 of 125 patients who
Table IV. Multivariable analysis for aneurysm-related complications, secondary interventions and overall mortality
Aneurysm-related
complications Secondary interventions Overall mortality
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age 1.01 .98-1.02 .91 .98 .95-1.03 .08 1.05 1.03-1.08 <.001
Male sex .91 .55-1.50 .72 .90 .49-1.66 .75 1.14 .72-1.80 .58
eGFR <60 mL/min/1.73 m .56 .36-.85 .008 .50 .29-.86 .01 1.72 1.26-2.36 .001
r-EVAR (vs el-EVAR) .94 .54-1.61 .81 .97 .50-1.86 .93 .62 .35-1.11 .11
a Angle >45 1.31 .80-2.17 .28 1.22 .66-2.26 .52 1.03 .59-1.72 .99
b Angle >60 1.30 .85-1.99 .22 1.26 .75-2.13 .39 .80 .51-1.25 .33
Neck length <15 mm 1.35 .83-2.19 .23 1.24 .68-2.26 .48 1.28 .77-2.13 .35
AUI device 1.8 .98-3.37 .06 2.05 .99-4.26 .05 1.46 .79-2.73 .23
Baseline AAA diameter 1.01 .99-1.02 .07 1.02 1.02-1.03 .02 1.01 1.01-1.02 .03
Reverse-tapered 1.26 .88-1.80 .21 .82 .51-1.33 .43 .86 .60-1.23 .41
AAA, Abdominal aortic aneurysm; AUI, aortouni-iliac; CI, confidence interval; eGFR, estimated glomerular filtration rate; el-EVAR, elective endovascular
aneurysm repair; HR, hazard ratio; PAD, peripheral arterial disease; r-EVAR, endovascular repair of a ruptured abdominal aortic aneurysm.
HRs and the CIs are presented per unit increase. Variables included in the multivariable model: age, gender, creatinine clearance <60 mL/min/1.73,
rupture as indication, alfa angle >45 , beta angle >60 , neck length <15 mm, AUI device, AAA diameter, and reverse tapered neck.
Fig 2. Kaplan-Meier curve for freedom from neck-related
events between endovascular repair of a ruptured
abdominal aortic aneurysm (r-EVAR) and elective endo-
vascular aneurysm repair (el-EVAR). Kaplan-Meier curves
only include data from patients with two postoperative
examinations. SE, Standard error.
Fig 3. Kaplan-Meier curve for freedom from secondary
interventions between endovascular repair of a ruptured
abdominal aortic aneurysm (r-EVAR) and elective endo-
vascular aneurysm repair (el-EVAR). Kaplan-Meier curves
only include data from patients with two postoperative
examinations. SE, Standard error.
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90 days and 3 years after EVAR.17 In the IMPROVE trial,
most of the reinterventions were performed early in the
postoperative period, and decreased during time. In
our study, 12.3% of patients have been reintervened
during index hospitalization, which is a slightly lower
than found in the first 90 days of the IMPROVE trial (40
reinterventions in 29 of 185 patients). This little difference
might easily be explained by the fact we only considered
in-hospital period/30-day as early reintervention, whereas
90 days were considered in the IMPROVE trial. In favor of
our argument, Broos et al6,17 found an even lower reinter-
vention rate during hospitalization (3.4%) compared with
our study.In our study, use outside the IFU was found to be pre-
dictive of secondary interventions, whereas the IMPROVE
trial reported a relevant association with the iliac anat-
omy.17 For those patients developing complications in
the IMPROVE trial, it would be relevant to analyze the
anatomic characteristics leading to an increased risk of
complications. Nevertheless, as with the IMPROVE trial,
our study suggests that in selected patients, r-EVAR is
able to achieve similar results up to midterm follow-up
as if performed in intact AAAs.
In our study, r-EVAR patients were not at an increased
risk of developing types I and III endoleaks when
compared with el-EVAR patients despite themorpholog-
ically distinctly different anatomies, with the r-EVAR
Fig 4. Kaplan-Meier curve of overall-survival after endo-
vascular repair of a ruptured abdominal aortic aneurysm
(r-EVAR) and elective endovascular aneurysm repair
(el-EVAR). Kaplan-Meier curves only include data from
patients with two postoperative examinations. SE, Stan-
dard error.
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necks. Quinn et al7 (n¼ 2052) also foundcomparable rates
of type I endoleaksbetween r-EVARpatients (5.4%) andel-
EVAR (4.4 %; P ¼ .68) over a mean follow-up period of
30 months. Although the rates of type I endoleaks
reported byQuinn et al7 are lower than the ones observed
in our cohort, our population had a longer follow-up
(4.3 years vs 2.5 years). In contrast, Broos et al6 found a
significantly higher incidence of type I and III endoleaks
among r-EVAR patients (21.3% vs 10%; P ¼ .003) at 5 years.
The presence ofmore complex anatomies among r-EVAR
patients combined with the emergency of the procedure
may have increased likelihood for device IFU violation,
which could explain the higher incidence of type I and
III endoleaks in r-EVAR group, although this was not dis-
closed by those authors.18,19 In our study, we specifically
addressed this question and found that patients treated
outside the IFU were at greater risk for neck-related com-
plications both in r-EVAR and el-EVAR groups. These data
are corroborated by Baderkhan et al19 in a multicenter
study, including some of the patients figuring in our cur-
rent report. Accordingly, graft-related complications
were more common among r-EVAR patients treated
outside IFU (30%; 95% CI, 14%-42%) when compared
with inside the IFU r-EVAR (6%; 95% CI, 0%-13%;
P ¼ .015).19 Consequently, our data suggest that adequate
sealing and IFU compliance rather than the timing of AAA
repair are more important determinants of outcomes
after EVAR. Furthermore, after being successful in obtain-
ing initial exclusion of the rupturedAAAand survival of the
patient, standard infrarenal r-EVAR when performed
outside proximal neck IFU should regularly be considered
as an intermediate step of a staged definitive repair,
because these patients will have a similar life expectancy
to el-EVAR patients.Additionally, our data underline the evolution of stan-
dard aortic infrarenal endografts, with late generation
devices outperforming older ones.20 Whereas in the
study from Broos et al the Talent (Medtronic, Santa
Rosa, Calif) was used in 63.3% of r-EVAR cases (vs 30.8%
of el-EVAR procedures) in our population the Endurant
(Medtronic) was most commonly implanted device for
r-EVAR. A comparative study from t’Mannetje et al21
found that the Talent was associated to an increased
risk of proximal neck complications (odds ratio, 6.73;
95% CI, 1.65-27.4) when compared with the Endurant
endoprosthesis as that device lacks active fixating such
as hooks and barbs. These findings may also explain
why r-EVAR patients had more type I and III endoleaks
in the study by Broos et al. In our study, patients who
died in hospital or were intraoperatively converted to
open repair were excluded, which probably leaves out
from the study a proportion of patients with a signifi-
cantly hostile anatomy. Additionally, the Endurant stent
graft was implanted in approximately 70% of r-EVAR
group and the latter has the broadest IFU criteria.
Furthermore, during study period approximately 50%
of rAAA had open repair. These reasons contributed for
a relatively low incidence of patients outside IFU in our
r-EVAR surviving population.
Aneurysm rupture represents the last stage of aortic
aneurysm disease progression. Consequently, after
excluding in-hospital mortality, a worse long-term sur-
vival might be anticipated in patients with a ruptured
AAA when compared with patients treated for el-AAA.
However, in our study, after discharge, long-term mortal-
ity was not significantly different among groups at 5 years,
in agreement with previous reports.4 In fact, a similar
burden of other competing cardiovascular diseases was
found among groups, which may be a more ominous
proxy of long-term survival than timing of repair.
There are several additional limitations that warrant
consideration. First, the retrospective nature of our study,
which is also from a single center, has the potential risk of
selection bias. A randomized controlled trial would de-
creases the risk of bias, but would not entirely eliminate
the procedure operator dependent and requires careful
planning. The selection of patients with at least two post-
operative examinations may give a biased estimate of
survival, because patients have to survive for at least
6 months after EVAR; however, overall survival including
these patients is provided in a supplementary analysis.
Another limitation of this study was the difficulty in
accessing the exact cause of death in all patients who
died during the study period. These data were obtained
from medical records, so caution is advised in the inter-
pretation of the mortality-related data. Method of repair
and type of device was left to the operator’s choice. In
addition, the lack of statistical power may have
hampered the possibility to unveil subtler differences
among patient groups. However, this study provides
10 Oliveira-Pinto et al Journal of Vascular Surgery
--- 2019midterm data of ruptured and el-EVAR patients which
may be combined with data from other studies and
constitute relevant information for further future analysis.
CONCLUSIONS
Our study suggests that, after discharge, durable
midterm outcomes results may be achieved in both elec-
tive and ruptured EVAR settings. Studies with a larger
sample size and longer follow-up are needed to confirm
safety of similar follow-up strategies in both groups.
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Supplementary Fig (online only). Kaplan-Meier curve of
overall-survival after endovascular repair of a ruptured
abdominal aortic aneurysm (r-EVAR) and elective endo-
vascular aneurysm repair (el-EVAR), including patients
previously excluded owing to a lack of two postoperative
examinations. SE, Standard error.
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